Skip to content

Management of Infant Digestive Disorders and Quality of Life

Management of Infant Digestive Disorders and Quality of Life

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04462640
Enrollment
101
Registered
2020-07-08
Start date
2020-08-28
Completion date
2021-11-17
Last updated
2022-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Dysfunction, Infant Nutrition Disorders

Keywords

Quality of life, Infants, Regurgitation, Colic

Brief summary

The objective of the study is to measure the evolution of the quality of life in infants between 0 and 5 months old, not breastfed and suffering from regurgitation or colic.

Detailed description

The objective of the study is to measure the evolution of the quality of life in infants between 0 and 5 months old, not breastfed and suffering from regurgitation or colic, following nutritional management of these disorders by a preparation for thickened infants, reduced in lactose content and supplemented with Lactobacillus reuteri DSM 17938. Quality of life is assessed using the QUALIN questionnaire

Interventions

OTHERManagement of Infant Digestive Disorders and Quality of Life

The variation of the QUALIN score on D30 compared to inclusion (D0) will be described and compared using a Student test for paired data in the case of a normal distribution or a test of the ranks signed by Wilcoxon otherwise.

Sponsors

Keyrus Biopharma
CollaboratorOTHER
Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Weeks to 4 Months
Healthy volunteers
Yes

Inclusion criteria

Full-term infants (\> 37 weeks gestation and \<42 weeks gestation), less than 4 months of age at recruitment * Infants with regurgitation and / or colic defined according to Rome IV criteria * Non-breastfed infants * Parents who understand and speak French fluently * Parents agreeing to send their email address and having a computer tool (computer, tablet or smartphone) allowing them to complete the QoL questionnaires and the satisfaction questionnaire * Parents having understood the protocol and the information given and having given the participation agreement including their acceptance to return for consultation with the same doctor after a period of 30 days.

Exclusion criteria

Infant born prematurely (\<37 weeks) • Intercurrent pathology other than a functional intestinal disorder which can by themselves cause, directly or as a result of treatments, a functional intestinal disorder: Study Management of infant digestive disorders and Quality of life * Food allergy * Digestive pathology (Gastroenteritis, celiac disease, high or low digestive malformations….) * Heart failure, cyanogenic heart disease * Chronic respiratory diseases (bronchopulmonary dysplasia, malformations, respiratory failure) * Neurological pathologies (Cerebral palsy, intracranial hypertension, convulsive state) * Congenital metabolic pathologies * Genetic diseases * Kidney malformations, Vesicoureteral reflux, Kidney failure. * Drug treatment in progress and which will be continued during the study, other than vitamins (D, K, ...) * Partial or total breastfeeding * Infants already fed: * with a hypoallergenic formula (HA) * or with a high hydrolyzate of cow's milk proteins or formula based on rice protein hydrolyzate * Growth retardation (weight and or height less than or equal to - 2 DS) or break in the weight curve (no weight gain or weight loss in the past month) Prescription of drugs or food supplements other than vitamins at the end of the visit

Design outcomes

Primary

MeasureTime frameDescription
Quality of life in infants with regurgitation and colic4 monthsThe main endpoint will be an increase in the QUALIN (QUALIté de vie du Nourrison) score on D30 compared to inclusion (D0) according to the 2 groups of patients: regurgitation only and colic only. This score is between -68 to +68. An increase in score means an improvement in symptoms.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026